The dynamism of Dynavax Technologies Corporation (NASDAQ:DVAX)


Dallas, Texas 09/09/2013 (Financialstrend) – In Friday’s trading session, Dynavax Technologies Corporation (NASDAQ:DVAX) dropped by 0.84%. The opening price of the shares was $1.21 which touched an intraday high of $1.25 and closed at $1.18. More than 2.54 million shares were traded on Friday while the average volume of shares traded over 30 days was 1.39 million. DVAX has a market cap of $215.93 million.

DVAX is essentially a clinical-stage biopharma company. It is involved in discovering and developing products that are used in the prevention and treatment or various inflammatory and infectious diseases. HEPLISAV, is its product candidate. It is a Phase III investigational adult-hepatitisB vaccine. It is designed to provide earlier and higher protection with lesser dosage than other licensed vaccines. DVAX’s pipeline of products include HEPLISAV. This is the company’s autoimmune-program that is partnered with GlaxoSmithKline. Its asthma therapy is partnered with AstraZeneca.


HEPLISAV is the company’s investigational adult-hepatitisB vaccine. DVAX has global commercial rights to this vaccine. It combines its 1st generation 1018 ISS with the hepatitis B surface antigen that is manufactured in the company’s Dynavax Europe facility located in Dusseldorf, Germany.

Universal Flu Vaccine

Dynavax Technologies Corporation (NASDAQ:DVAX) Universal Flu vaccine offers protection against divergent-influenza strains. It also increases the efficacy and potentially reduces the antigen-content of various standard flu vaccines. This approach is based on N8295, its component. This is a fusion-protein that is comprised of 2 highly conserved influenza-antigens, matrix protein 2 (M2e) and nucleoprotein (NP).

These are covalently linked to 2nd-generation ISS. The company is also developing DV1179. This is a bi-functional inhibitor of TLR9 and TLR7, under a global alliance with GSK. The company’s IRS program focuses on TLR inhibitors for diseases like psoriasis and lupus.  As of 31 December 2011, the company’s intellectual portfolio included 18 different issued U.S patents. These claim formulations and compositions of immunostimulatory sequences and IRS, their processes or methods of usage.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.